# US 2013/0158662 A1 · Muscle Derived Cells For The Treatment Of Gastro-Esophageal Pathologies And Methods Of Making And Using The Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158662 A1
- Document ID: US20130158662A1
- Status: Published application
- Kind: A1
- Application number: 13/766,894
- Filed: 2013-02-14
- Published: 2013-06-20
- Earliest claimed: 2006-12-18
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Inventors: Michael B. Chancellor; Jay Pasricha; Ronald Jankowski; Ryan Pruchnic
- Web page: https://patentgrep.com/patent/US20130158662A1

## CPC

- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61F 2/04: Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts (A61F2/18, A61F2/20 take precedence; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95)
- A61F 2/08: Muscles; Tendons; Ligaments
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- C12N 5/0658: {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}
- A61F 2002/044: {Oesophagi or esophagi or gullets}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61M 2202/09: Body tissue
- C12N 2500/38: Vitamins
- C12N 2501/105: Insulin-like growth factors [IGF]
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/165: Vascular endothelial growth factor [VEGF]
- C12N 2501/39: Steroid hormones
- C12N 2501/91: Heparin
- C12N 2509/00: Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N 2533/54: Collagen; Gelatin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration of symptoms for gastro-esophageal pathologies like gastro-esophageal reflux.

## Claims

### Claim 1

A method of increasing lower esophageal sphincter pressure in a mammalian subject comprising:
(a) isolating skeletal muscle cells from the mammalian subject;
(b) cooling the cells to a temperature lower than 10° C. and storing the cells for 1-7 days;
(c) suspending the mammalian skeletal muscle cells in media in a first cell culture container to which fibroblast cells of the skeletal muscle cells adhere, for between 30 and 120 minutes;
(d) decanting the media containing non-adherent cells from the first cell culture container to a second cell culture container;
(e) allowing the remaining non-adherent cells in the media in step (d) to attach to the walls of the second cell culture container;
(f) isolating the cells from the walls of the second cell culture container, wherein the isolated cells are muscle-derived progenitor cells (MDCs);
(g) culturing the isolated MDCs to expand their number;
(h) freezing the MDCs to a temperature below −30° C.;
(i) thawing the MDCs; and
(j) administering the MDCs to the esophagus of the mammalian subject, thereby increasing lower esophageal sphincter pressure by at least about 50% in the mammalian subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the skeletal muscle cells are isolated from the mammalian subject before a gastro-esophageal reflux disease begins in the mammalian subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the increase in lower esophageal sphincter pressure is increased by at least about 100%.

### Claim 4 (depends on 1)

The method of claim 1, wherein the MDCs are administered by injecting them into the esophagus.

### Claim 5 (depends on 1)

The method of claim 1, wherein the administering step involves injecting the MDCs into the lower esophageal sphincter.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mammalian subject is a human.

### Claim 7

A method of increasing lower esophageal sphincter pressure in a mammalian subject comprising:
(a) isolating skeletal muscle cells from the mammalian subject,
(b) suspending the mammalian skeletal muscle cells in media in a first cell culture container for between 30 and 120 minutes;
(c) decanting the media from the first cell culture container to a second cell culture container;
(d) allowing the remaining cells in the media to attach to the walls of the second cell culture container;
(e) isolating the cells from the walls of the second cell culture container, wherein the isolated cells are muscle-derived progenitor cells (MDCs); and
(f) administering the MDCs to the esophagus of the mammalian subject; thereby increasing lower esophageal sphincter pressure in the mammalian subject.

### Claim 8 (depends on 7)

The method of claim 7, wherein the increase in lower esophageal sphincter pressure is increased by at least about 100%.

### Claim 9 (depends on 7)

The method of claim 7, wherein the MDCs are administered by injecting them into the esophagus.

### Claim 10 (depends on 9)

The method of claim 9, wherein the MDCs are injected into the lower esophageal sphincter.

### Claim 11 (depends on 7)

The method of claim 7, wherein the mammalian subject is a human.

### Claim 12 (depends on 7)

The method of claim 7, wherein the MDCs are cultured to expand their number before being administered to the esophagus of the mammalian subject.

### Claim at position 13

13-17. (canceled)
